World Lung Cancer Day: Risks of vaping; an ‘unprecedented’ advance in ALK-positive disease
Click Here to Manage Email Alerts
Today is World Lung Cancer Day.
The observance — held annually on Aug. 1 — is intended to raise awareness about the impact of lung cancer.
In conjunction with World Lung Cancer Day, Healio presents the following important updates in treatment and research.
1. Adjuvant durvalumab (Imfinzi, AstraZeneca) failed to improve outcomes compared with placebo for patients with early-stage non-small cell lung cancer who underwent complete tumor resection. Read more.
2. However, durvalumab conferred a significant survival benefit to patients with limited-stage small-cell lung cancer following standard treatment. Read more.
3. Lorlatinib (Lorbrena, Pfizer) delivered never-before-seen PFS results for adults with anaplastic lymphoma kinase-positive NSCLC. The agent also delayed disease progression and development of brain metastases compared with crizotinib (Xalkori, Pfizer). Read more.
4. Individuals with KRAS-mutant lung cancer treated with adagrasib (Krazati, Bristol Myers Squibb) achieved significantly longer PFS than those who received docetaxel. Read more.
5. People who vaped and smoked cigarettes appeared four times more likely to develop lung cancer compared with those who only smoked. Read more.
6. Osimertinib (Tagrisso, AstraZeneca) following chemoradiotherapy greatly improved PFS compared with placebo for patients with advanced EGFR-mutant NSCLC. Read more.
7. Early palliative care via telehealth had an equivalent impact on quality of life as in-person visits for patients with advanced NSCLC. Read more.
8. Researchers at Keck Medicine of USC launched the first clinical trial to evaluate the feasibility of at-home, subcutaneous immunotherapy treatment for NSCLC. The trial will investigate whether a new formulation of atezolizumab (Tecentriq, Genentech/Roche) can be safely and effectively delivered subcutaneously by a nurse in the patient’s home rather than via IV in a clinic or hospital setting. Read more.
9. Researchers developed a miniature “tumor farm” model that uses biopsied tumor cells to enable personalized, 3-D testing of the cells’ response to various lung cancer drugs. Read more.
10. Black patients and those with interstitial fibrosis or advanced-stage disease had a higher risk for developing clinically detectable postoperative venous thromboembolism after pulmonary resection for lung cancer. Read more.
Collapse
Healio Coverage
Click Here to Manage Email Alerts